Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study
about
Acute lymphoblastic leukaemiaMercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fictionModel-Based Individualized Treatment of Chemotherapeutics: Bayesian Population Modeling and Dose OptimizationMyelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activityThe Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009.Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseA revised definition for cure of childhood acute lymphoblastic leukemia.Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.Epidemiology of therapy-related myeloid neoplasms after treatment for pediatric acute lymphoblastic leukemia in the nordic countries.Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance.Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment.Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review.Secondary Solid Organ Neoplasm in Patients with Acute Lymphoblastic Leukemia: A Nationwide Population-Based Study in Taiwan.Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia.Folate levels modulate oncogene-induced replication stress and tumorigenicityPediatric acute lymphoblastic leukemia: where are we going and how do we get there?Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemiaRelative fitness of hematopoietic progenitors influences leukemia progression.Screening of cytoprotectors against methotrexate-induced cytogenotoxicity from bioactive phytochemicals.Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.Pharmacogenomics of pediatric acute lymphoblastic leukemia.Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia.Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants.Cancer pharmacogenomics in children: research initiatives and progress to date.Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.Optimizing treatment in paediatric rheumatology--lessons from oncology.Can anthocyanins improve maintenance therapy of Ph(+) acute lymphoblastic leukaemia?Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?Leukemic blasts are present at low levels in spinal fluid in one-third of childhood acute lymphoblastic leukemia cases.The homologous recombination protein RAD51D mediates the processing of 6-thioguanine lesions downstream of mismatch repair.Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia.Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children.Host genome variations and risk of infections during induction treatment for childhood acute lymphoblastic leukaemia.Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy?
P2860
Q24602387-D28A4E88-73E3-45DA-BCA5-E1B9833F0443Q27023839-50F7EB16-3A5F-40C3-8EEC-6964ADDE3949Q28546915-D36AB4D8-CEFA-4E37-BD46-445C9132FE9FQ33418418-BCB9E9BF-5E42-4852-961E-07546DC82C07Q33636082-A0B13EB9-ABA9-46C6-B9E6-2D0CD761931EQ33637143-D5D72DF4-8DD2-45A6-B820-652897C72167Q33674158-EAA65B46-8EDC-42FB-989C-4B20B1001512Q34429332-DF4E27BD-FCCF-4FB4-903C-B60260935C39Q34478851-30B9DB37-9FFA-4CC9-AE79-24126EFE3296Q35040001-A6BFD5B9-61F9-414C-95B8-646A29A2A698Q35206306-E822D1D1-9276-46F1-A5AC-B6C8629893ECQ35327001-F8E1429E-3523-46AB-AAF4-336174371A75Q35971977-D8714A30-A52B-4858-876A-7D00C732FFA1Q35976536-9CF0D931-6284-48ED-B774-ABAA54336140Q35984724-703DD23A-A32D-4C86-A28D-518C5F68F778Q36057574-B5918194-5802-40DE-ACA9-DAC73099069EQ36163029-D5C76103-8BF8-47FD-84F5-FD640A199075Q36532537-C541A573-24EB-4D93-B30B-2420584C0B31Q36605135-967470D0-E065-4C2C-B0B2-AF9E37B94CB7Q36895929-A374AAA6-F5D3-4F05-96E1-C74860257885Q36903346-17BB6DCB-DFE4-4B68-9EB0-FC84A5021AFEQ37087479-E92DA36E-772F-457F-8FB9-4937B24ED06BQ37252283-679AF2BF-B508-428C-8CC1-7055C1531A1DQ37658863-A1DB750E-B321-49AF-8723-53327EFC02ABQ37739432-A03039E0-8F74-4323-9C2A-5C4671431E00Q37929894-0B246AC1-895B-4D7C-B977-73240DF22F4DQ38003177-6576C9BB-E0F1-4F9B-BCBB-21A57F462A39Q38093137-5F5BD578-1CBC-4E5E-9E44-65EC80ADD9ACQ38264774-1404960F-6B1D-4211-9D75-CCE884E28294Q38289596-47526053-97AC-4C1E-853B-1D68186CD6AFQ38434311-13BA7B02-3982-4CBA-99AB-45E9E0569EDEQ39215315-8B172382-29FB-4AB4-8C73-56CB85C9CCCAQ39570917-9748CF5B-3144-445C-944D-2E252F045B02Q39571116-811CD55F-02AE-4B91-9B64-646C7F2F9771Q39612328-E2AA3091-4E17-47B5-833F-B2B6861D6CE8Q39785801-96C96BD6-6754-41D9-A1CB-B82CA3002844Q40314940-2ABF7CB8-8D37-4485-9FBF-6A43F3FB4B19Q40518805-ADC07EF1-10A1-464E-9535-70DCB51F0BC9Q42237227-C3407AEB-0E72-4440-9D4B-13AD66BF3ADEQ42319267-F835D709-2901-4C5A-AF02-3C05FCE177DE
P2860
Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Methotrexate/6-mercaptopurine ...... ts from the NOPHO ALL-92 study
@en
Methotrexate/6-mercaptopurine ...... s from the NOPHO ALL-92 study.
@nl
type
label
Methotrexate/6-mercaptopurine ...... ts from the NOPHO ALL-92 study
@en
Methotrexate/6-mercaptopurine ...... s from the NOPHO ALL-92 study.
@nl
prefLabel
Methotrexate/6-mercaptopurine ...... ts from the NOPHO ALL-92 study
@en
Methotrexate/6-mercaptopurine ...... s from the NOPHO ALL-92 study.
@nl
P2093
P2860
P50
P1433
P1476
Methotrexate/6-mercaptopurine ...... ts from the NOPHO ALL-92 study
@en
P2093
Anne Louise Svendsen
Erik Forestier
Ibrahim Al-Modhwahi
Jacob Nersting
Jon Kristinsson
Kim Vettenranta
Mats Heyman
Mikael Behrendtz
Nordic Society for Paediatric Haematology and Oncology
Randi Nygaard
P2860
P304
P356
10.1182/BLOOD-2008-11-187880
P407
P577
2009-02-17T00:00:00Z